<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Anderson EMS Pocket Medic</title>
    <link rel="icon" href="../favicon.ico" type="image/png" />
    <link rel="stylesheet" href="../AdultMedical.css" />
    <link rel="stylesheet" href="Allergic.css" />
  </head>
  <body>
    <a href="../../../index.html" class="header-link">
      <div class="header">
        <h1>Anderson EMS Pocket Medic</h1>
      </div>
    </a>
    
    <div class="MainBody">
      <h2>Allergic Reaction /<br>
        Anaphylaxis</h2>

      <div class="InitialBody">

        <table class="StartTable">
            <thead>
                <tr>
                    <th>History</th>
                    <th>Signs and Symptoms</th>
                    <th>Differential</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>
                        • Onset and location<br><br>
                        • Insect sting or bite<br><br>
                        • Food allergy / exposure<br><br>
                        • Medication allergy / exposure<br><br>
                        • New clothing, soap, detergent<br><br>
                        • Past history of reactions<br><br>
                        • Past medication history
                    </td>
                    <td>
                        • Itching or urticaria<br><br>
                        • Coughing, wheezing, or respiratory
                        distress<br><br>
                        • Chest tightness or throat constriction<br><br>
                        • Hypotension or shock<br><br>
                        • Persistent gastrointestinal symptoms
                        (nausea, vomiting, and diarrhea)<br><br>
                        • Altered mental status
                    </td>
                    <td>
                        • Angioedema (drug induced)<br><br>
                        • Aspiration / Airway obstruction<br><br>
                        • Vasovagal event<br><br>
                        • Asthma or COPD<br><br>
                        • CHF
                    </td>
                </tr>
            </tbody>
        </table>
        <h3 class="AllLevels">EMR</h3>
        <p>
            1. <a href="../../General/UniversalSources/Universal.html" class="working-link" title="Universal Patient Care" >UNIVERSAL PATIENT CARE</a>.<br><br>

            2. If signs of <strong>ANAPHYLAXIS</strong>, administer and/or assist patient with 
            <a href="../../../DrugMaterial/Epi1000Folder/epi1000.html" class="working-link" title="Epi 1:1000" >EPINEPHRINE AUTOINJECTOR</a> <strong>(0.3mg > 30kg)</strong>
            <br><br>

            3. If respiratory distress with wheezing is present administer <a href="../../../DrugMaterial/AlbuterolFolder/albuterol.html" class="working-link" title="Albuterol Med Page ">
            ALBUTEROL</a>
             <strong>(5 mg)</strong> or <a href="../../../DrugMaterial/DuoNebFolder/duoneb.html" class="working-link" title="DuoNeb Med Page ">
            Pre-mix IPRATROPIUM BROMIDE/ALBUTEROL</a>
             <strong>(0.5 mg/3 mg)</strong> via nebulizer.<br><br>

            4. Relay information to incoming ambulance.
        </p>
        <h3 class="EMT">EMT</h3>
        <p>
            1. Continue <strong>EMR TREATMENT</strong>.<br><br>

            2. If signs of <strong>ANAPHYLAXIS</strong>, administer <a href="../../../DrugMaterial/Epi1000Folder/epi1000.html" class="working-link" title="Epi 1:1000" >EPINEPHRINE 1:1,000</a>
             <strong>(0.3-0.5) mg IM</strong> (may repeat x1 after 5-15
            minutes).<br><br>

            3. May repeat <a href="../../../DrugMaterial/AlbuterolFolder/albuterol.html" class="working-link" title="Albuterol Med Page ">
            ALBUTEROL</a> <strong>(5 mg)</strong> or <a href="../../../DrugMaterial/DuoNebFolder/duoneb.html" class="working-link" title="DuoNeb Med Page ">
            Pre-mix IPRATROPIUM BROMIDE/ALBUTEROL</a> <strong>(0.5 mg/3 mg)</strong> via
            nebulizer x 2, if needed for continued symptomatic relief.<br><br>

            4. For non-anaphylactic allergic reactions, consider <a href="../../../DrugMaterial/DiphenhydramineFolder/diphenhydramine.html" class="working-link" title="Diphenhydramine Med Page">
            DIPHENHYDRAMINE</a> <strong>50 mg PO</strong>.<br><br>

            5. Relay information to incoming ambulance and/or call for intercept per <a href="../../General/InterceptCriteriaSources/Intercept.html" class="working-link" title="
            Intercept Criteria Page">
            INTERCEPT CRITERIA</a>.

        </p>
        <h3 class="PARAMEDIC">Paramedic/PHRN</h3>
        <p>
                1. Continue <strong>BLS TREATMENT</strong>.<br><br>

                2. If signs of <strong>ANAPHYLAXIS</strong>, persist, repeat <a href="../../../DrugMaterial/Epi1000Folder/epi1000.html" class="working-link" title="Epi 1:1000" >EPINEPHRINE 1:1,000</a>
                <strong>(0.3-0.5) mg IM</strong> every 5-15 minutes.
                (Max 3 doses)<br><br>

                3. Establish IV access.<br><br>

                4. Administer Isotonic solution <strong>500 mL</strong> bolus to maintain SBP ≥ 90 mmHg or MAP ≥ 65 mmHg. Repeat fluid
                bolus as needed as long as lungs remain clear to maintain SBP ≥ 90mmHg or MAP ≥ 65 mmHg; maximum <strong>2 liters</strong>.<br><br>

                5. <a href="../../../DrugMaterial/DiphenhydramineFolder/diphenhydramine.html" class="working-link" title="Diphenhydramine Med Page">
                     DIPHENHYDRAMINE</a> <strong>50 mg IM/IV/IO/PO</strong>. (Not to be repeated if already given by BLS provider) <i>May be
                given without epinephrine for incidents involving <u>isolated</u> urticaria, hives or angioedema that <u>does not</u> involve
                the mouth, lips or airway</i>
                <br><br>

                6. <a href="../../../DrugMaterial/MethylprednisoloneFolder/Methylprednisolone.html" class="working-link" title="METHYLPREDNISOLONE Med Page">
                     METHYLPREDNISOLONE</a> <strong>125 mg IV/IM/IO</strong> or <a href="../../../DrugMaterial/DexamethasoneFolder/dexamethasone.html" class="working-link" title="DEXAMETHASONE Med Page">
                     DEXAMETHASONE</a> <strong>10 mg IV/IO</strong>.<br><br>

                7. Closely monitor respiratory status with <a href="#" class="placeholder-link" title="Page coming soon">waveform capnography</a> and reassess need for intubation if respiratory
                symptoms worsen or do not improve with treatment. See 
                <a href="../../General/AirwayManagementSources/AirwayManagement.html" class="working-link" title="Airway Management Protocol">
                     AIRWAY MANAGEMENT</a> Protocol.
        </p>
        <p>
            <strong>PEARLS</strong><br><br>

                • Allergic reactions and anaphylaxis are serious and potentially life-threatening medical emergencies.<br><br>

                • The shorter the onset from exposure to symptoms, the more severe the reaction.<br><br>

                • Localized allergic reactions (e.g. urticarial or angioedema that does not involve the mouth, lips or airway,
                may be treated with antihistamine therapy.<br><br>

                • Anaphylaxis should always be treated with Epinephrine as first-line treatment.<br><br>

                • Cardiovascular collapse may occur abruptly, without the prior development of skin or respiratory symptoms.<br><br>

                • Always perform cardiac monitoring when administering Epinephrine<br><br>
                <span class="Indention">
                    -Cardiac monitoring should not delay administration of Epinephrine
                </span>
                <strong>Definitions</strong><br><br>

                • <strong>Anaphylaxis</strong> — More severe and characterized by an acute onset involving:<br><br>
                <span class="Indention">
                    1) Skin (urticaria) and/or mucosa with either respiratory compromise or hypotension (SBP &lt; 90
                    mmHg) or signs of end-organ dysfunction<br><br>
                    
                    <span class="Indention">
                            <strong>-OR-</strong><br><br>
                    </span>
                    
                    1) Hypotension (SBP &lt;  90 mmHg) for that patient after exposure to a <strong>known</strong> allergen<br><br>

                    <span class="Indention">
                            <strong>-OR-</strong><br><br>
                    </span>
                    
                    1) Two or more of the following occurring rapidly after exposure to a likely allergen:<br><br>
                
                    <span class="Indention">
                        i. Skin and/or mucosal involvement (urticaria, itchy, swollen tongue / lips)<br><br>
                        ii. Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)<br><br>
                        iii. Persistent gastrointestinal symptoms (vomiting, abdominal pain, diarrhea)<br><br>
                        iv. Hypotension or associated symptoms (syncope, hypotonia, incontinence)<br><br>
                    </span>
                </span>
                • <strong>Non-Anaphylactic Allergic Reaction</strong> — Signs involving only <strong><u>one</u></strong> organ system 
                (e.g. localized angioedema that does not compromise the airway or not associated with vomiting; urticaria alone).
        </p>

      

        <table class="EndTable">
          <thead>
            <tr>
              <th><strong>KEY DOCUMENTATION ELEMENTS </strong></th>
              <th><strong>PERTINENT ASSESSMENT FINDINGS </strong></th>
            </tr>
          </thead>
          <tbody>
            <tr>
                <td>
                    • Medications given<br><br>
                    • Dose and concentration of Epinephrine given<br><br>
                    • Route of Epinephrine administration<br><br>
                    • Time of Epinephrine administration<br><br>
                    • Signs and symptoms of the patient<br><br>
                    • Waveform capnography for anaphylaxis
                </td>
                <td>
                    • Presence or absence of angioedema<br><br>
                    • Presence or absence of respiratory compromise<br><br>
                    • Presence or absence of circulatory compromise<br><br>
                    • Localized or generalized urticaria<br><br>
                    • Response to therapy
                </td>
            </tr>
          </tbody>
        </table>
         <table class="QMTable">
          <tr>
            <td>
              <strong>QUALITY METRICS</strong><br /><br />
            </td>
          </tr>
          <tr>
            <td>
                • Percentage of patients with anaphylaxis that receive Epinephrine<br><br>
                • Airway assessment documented

            </td>
          </tr>
        </table>

      </div>
    </div>
          <script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
    <script src="Allergic.js"></script>
  </body>
  <footer class="footer">
    <p>&copy; 2025 LukiSoft. All rights reserved.</p>
  </footer>
</html>
